Patients don’t always take their medication, and the results can be tragic. Take asthma. Every 10 seconds someone has a severe asthma attack, and 3 people in the UK die daily. Asthma cannot be cured but can be controlled by taking medication regularly, and on time. No new medication or drugs are required. Medical adherence is the biggest opportunity to improve quality of life and reduce fatalities. A change in habit is what’s needed.
Aerobit’s Asthma Care Platform is a total solution to address medical non-adherence for asthma sufferers. A “Smart Inhaler Jacket” comprising multiple sensors, GPS and Bluetooth—monitors when the inhaler was taken, how was it taken (less than one in five patients are using them properly) and makes this data available to patients, family and clinicians through a smartphone app and the cloud. Forgot a dose? The Aerobit app sends a reminder to the patent (and also let parents know as necessary). Aerobit’s Asthma Care Platform offers peace of mind to families of asthma patients.
There’s a lot more under the hood. The device can also collect data like weather conditions, pollen and humidity and compare it with times rescue inhalers were taken. The benefit is a recorded pattern of asthma triggers unique to the patient—invaluable info for doctors and patients alike.
Improving medication adherence is a multi-billion dollar opportunity in the coming decade, and Aerobit is uniquely positioned to service this huge market. Aerobit makes managing asthma easier and more effective than ever.
The Aerobit Asthma Care Platform is purposely designed for use in the asthma medication management field to increase adherence. This is where we have identified a gap in the market where the product can make a dramatic impact on the sobering asthma statistics. That is not to say it is the sole medical field where we believe the product can have an impact, but it is our primary target.
Our initial market therefore, is asthma and COPD sufferers in the UK & EU—followed by an international roll-out within 5 years. With the number of people with asthma expected to grow to 400 million by 2025, this is a global model. Aerobit aim to focus initially on the UK and EU, and then branch into other territories once we are an established brand at home. To achieve growth, we will be creating partnerships with Healthcare organizations like the NHS, insurance companies like BUPA, pharmaceutical companies specializing in manufacturing inhalers like CIPLA, GSK, AZ, and also with healthcare retailers.